Comparative therapeutic potential of ALX-0171 and palivizumab against RSV clinical isolate infection of well-differentiated primary pediatric bronchial epithelial cell cultures

1 Comparative therapeutic potential of ALX-0171 and palivizumab against RSV clinical isolate 1 infection of well-differentiated primary pediatric bronchial epithelial cell cultures 2 3 Lindsay Broadbent a , Hong Guo Parke a , Lyndsey J. Ferguson a , Andrena Miller a , Michael D. 4 Shields a,b , Laurent Detalle c , Ultan F. Power a #. 5 6 a Wellcome-Wolfson Institute for Experimental Medicine, Queens University Belfast, Belfast, 7 United Kingdom 8 b Royal Belfast Hospital for Sick Children, Belfast Health & Social Care Trust, Belfast, United 9 Kingdom 10 b Ablynx nv, Belgium 11 12 Running Head: Efficacy of ALX-0171 against two RSV strains 13 14 # Address correspondence to Professor Ultan Power [email protected] 15 16 . CC-BY-ND 4.0 International license a certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under The copyright holder for this preprint (which was not this version posted October 10, 2019. ; https://doi.org/10.1101/800326 doi: bioRxiv preprint

Comparative therapeutic potential of ALX-0171 and palivizumab against RSV clinical isolate infection of well-differentiated primary pediatric bronchial epithelial cell cultures

Others